Steven Waggoner

7.9k citations

136 papers · 5.0k indexed · 1 hit paper · h-index 38

Impact in

Obstetrics and Gynecology top 0.2%
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment

Papers in

Obstetrics and Gynecology 64
- Endometrial and Cervical Cancer Treatments 63
- Uterine Myomas and Treatments 10
Reproductive Medicine 59
- Ovarian cancer diagnosis and treatment 58

Co-authors: Jacob Rotmensch Arno J. Mundt John A. Blessing Vivian E. von Gruenigen S. Diane Yamada Heidi E. Frasure Gini F. Fleming Mary Kavanagh
Journals: Gynecologic Oncology (61 papers)Journal of Clinical Oncology (15 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)Cancer (3 papers)Technology in Cancer Research & Treatment (2 papers)
Partner nations: United States Canada Japan

In The Last Decade

Steven Waggoner

132 papers receiving 4.9k citations

Hit Papers

align trajectories log scale

Cervical cancer 2003 · 732 citations

Peers

Countries citing papers authored by Steven Waggoner

Since Specialization

Citations

This map shows the geographic impact of Steven Waggoner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Waggoner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Waggoner more than expected).

Fields of papers citing papers by Steven Waggoner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Waggoner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Waggoner. The network helps show where Steven Waggoner may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Steven Waggoner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Waggoner Line = papers co-authored together Steven Waggoner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study Gynecologic Oncology ·Victoria Bae‐Jump, Michael W. Sill, Paola A. Gehrig, Jason D. Merker, David L. Corcoran, Adam D. Pfefferle, Michele C. Hayward, Joan L. Walker, Andrea R. Hagemann, Steven Waggoner, Roisin E. O’Cearbhaill, Megan McDonald, Mitchell I. Edelson, Paul DiSilvestro, H. Abdel-Kader, Jingyue Xie, Ramey D. Littell, Frederick R. Ueland, Heather A. Lankes, Carol Aghajanian	2025	1
2	Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203 PubMed ·Kelsey L. Corrigan, Rebecca Paulus, Ann H. Klopp, Lari Wenzel, Anamaria R. Yeung, J. S. Thompson, Desiree E. Doncals, Vijayananda Kundapur, Boris Čok, Dasarahally S. Mohan, Sharad Ghamande, Shannon N. Westin, Khaled A’amar, Michael L. Haas, David K. Gaffney, Steven Waggoner, Emmanuelle Vivier Leloire, Noha Jastaniyah, Stephanie L. Pugh, Lisa A. Kachnic	2025	2
3	Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial Journal of Clinical Oncology ·Ann H. Klopp, Danielle Enserro, Matthew A. Powell, Marcus E. Randall, Julian C. Schink, Robert S. Mannel, Laura L. Holman, David Bender, L Fejérdy, Floor Backes, Susan Zweizig, Steven Waggoner, Kristin Bradley, Direttore Della, Parviz Hanjani, Christopher J. Darus, William Small, Higinia R. Cárdenes, Jonathan Feddock, David S. Miller	2024	10
4	A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results. Journal of Clinical Oncology ·Daron Street, A. Manten, David Starks, Haider Mahdi, Carlos Linn, Dmitri Pavlov, D. Sanchez Gonzalo, Sant P. Chawla, Ingmar Bruns, Steven Waggoner	2024	2
5	Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014) Gynecologic Oncology ·Alison M. Schram, Ramez N. Eskander, Michael W. Sill, Andrea R. Hagemann, Steven Waggoner, Joshua Z. Press, Sharad Ghamande, Oliver Zivanovic, Justin Bottsford-Miller, Carol Aghajanian	2024	1
6	LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa) Annals of Oncology ·Fernandez Ramon A. Suarez, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Cloven, Carolyn Y. Muller, David Bender, Richard G. Moore, Andrey Borisovich Daryenkov, Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, Michael E. Carney, Angeles Alvarez Secord, Kuno Schallenberg, Giuditta Leone	2023	2
7	PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009) Roisin E. O’Cearbhaill, Michael W. Sill, Jacinto Antonio Rivero Chávez, Steven Waggoner, Rachel N. Grisham, Floor Backes, Robert S. Mannel, János L. Tanyi, Matthew A. Powell, Cara Mathews, Sharad Ghamande, Leah McNally, Alexander Olawaiye, David Bender, Linda Duska, Heather A. Lankes, Dmitriy Zamarin, Russell J. Schilder, Michael A. Bookman, Carol Aghajanian	2023	0
8	LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004 Annals of Oncology ·Elizabeth M. Swisher, Austin Miller, Elise C. Kohn, Mark F. Brady, Marc R. Radke, Christopher C. Pennil, 박강수, Joseph Buscema, William P. Tew, Carolyn Y. Muller, Emily K. Hill, Richard G. Moore, Andrey Borisovich Daryenkov, Steven Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D’Andre, Zhang Yang, Michael J. Birrer	2021	4
9	The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis Cancer Research ·Sarah E. Taylor, Caitlin M. O’Connor, Zhizhi Wang, Guobo Shen, 岡本貴隆, Daniel Léonard, Jaya Sangodkar, Elmer Daniel Tejada Velásquez, Stefanie Avril, Steven Waggoner, Kristine Zanotti, Amy J. Armstrong, Christa Nagel, Kimberly Resnick, Sareena Singh, Mark W. Jackson, Wenqing Xu, Shozeb Haider, Analisa DiFeo, Goutham Narla	2019	42
10	Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study Gynecologic Oncology ·Haider Mahdi, Peter G. Rose, Lynn Rudich, Adnan Munkarah, Derek Isrow, Ren Shuzhi, Steven Waggoner, Rouba Ali‐Fehmi, Harry I. Subin, Dylan Tagrin, Pablo Noriega	2015	17
11	Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (SUCCEED): A randomized controlled trial Gynecologic Oncology ·Michele L. McCarroll, Shannon D. Armbruster, Heidi E. Frasure, M. David Gothard, Krzysztof Gil, Mary Kavanagh, Steven Waggoner, Vivian E. von Gruenigen	2013	72
12	Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): A randomized controlled trial Gynecologic Oncology ·Vivian von Gruenigen, Heidi E. Frasure, Mary Kavanagh, Jeffrey W. Janata, Steven Waggoner, Peter G. Rose, Edith Lerner, Kerry S. Courneya	2012	95
13	Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report Case Reports in Obstetrics and Gynecology ·David Starks, Wesley R. Barnhart, Amy J. Armstrong, Silvio Cezar de Souza Lima, Steven Waggoner, Robert Debernardo	2011	4
14	A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study Gynecologic Oncology ·Mark A. Morgan, Michael W. Sill, Keiichi Fujiwara, Benjamin E. Greer, Stephen C. Rubin, Koen DeGeest, S. Diane Yamada, Steven Waggoner, Robert L. Coleman, Joan L. Walker, Robert S. Mannel	2011	15
15	Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: A randomized trial Gynecologic Oncology ·Vivian E. von Gruenigen, Kerry S. Courneya, Heidi Gibbons, Mary Kavanagh, Steven Waggoner, Edith Lerner	2008	105
16	Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients International Journal of Radiation OncologyBiologyPhysics ·C Hanenberg Milver, Loren K. Mell, Jean Hurteau, Yvonne Collins, Jacob Rotmensch, Steven Waggoner, S. Diane Yamada, William Small, Arno J. Mundt	2005	70
17	Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy International Journal of Radiation OncologyBiologyPhysics ·Arno J. Mundt, Russell B. McBride, Jacob Rotmensch, Steven Waggoner, S. Diane Yamada, Philip P. Connell	2001	100
18	Acute Myelomonocytic Leukemia with Abnormal Eosinophils Presenting as an Ovarian Mass: A Report of Two Cases and a Review of the Literature Gynecologic Oncology ·Viive Kõvask, Steven Waggoner, Vismay R B Gowda, Rebecca Byrne, Richard A. Larson	1995	17
19	Clinical Assessment of 111In-CYT-103 Immunoscintigraphy in Ovarian Cancer Gynecologic Oncology ·Earl A. Surwit, Joel M. Childers, David N. Krag, Qingbo He, Holly H. Gallion, Steven Waggoner, William J. Mann	1993	38
20	Rapid dysplastic transformation of human genital cells by human papillomavirus type 18 Gynecologic Oncology ·Willard A. Barnes, Craig D. Woodworth, Steven Waggoner, Mark H. Stoler, A. Bennett Jenson, Gregorio Delgado, Joseph A. DiPaolo	1990	19

About Steven Waggoner

Steven Waggoner is a scholar working on Obstetrics and Gynecology, Reproductive Medicine, Oncology, Surgery and Epidemiology, having authored 136 papers that have together received 5.0k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (63 papers), Ovarian cancer diagnosis and treatment (58 papers), Cervical Cancer and HPV Research (25 papers), Intraperitoneal and Appendiceal Malignancies (17 papers), Colorectal and Anal Carcinomas (15 papers), Cancer survivorship and care (11 papers), Cancer Risks and Factors (11 papers) and Uterine Myomas and Treatments (10 papers). The work is most often cited by research in Obstetrics and Gynecology (2.0k citations), Reproductive Medicine (1.7k citations), Oncology (1.8k citations), Cancer Research (545 citations) and Radiation (253 citations). Steven Waggoner has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Jacob Rotmensch, Arno J. Mundt, John A. Blessing, Vivian E. von Gruenigen, S. Diane Yamada, Heidi E. Frasure, Gini F. Fleming, Mary Kavanagh, Parviz Hanjani and Charles A. Kunos. Their work appears in journals such as Gynecologic Oncology, Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer and Technology in Cancer Research & Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact